

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.51 Billion in May

保瑞公告 5 月自結合併營收新台幣 15 億 1 仟萬元

Taipei, Taiwan, June 9, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for May 2025 reached NT\$1.51 billion, a decrease of 10.7% compared to same period last year. Year-to-date revenues grew 35.0%. Affected by a weaker USD, revenues in May declined by 6.0% year-over-year when measured in USD terms. If April's exchange rate were applied, revenues would have been approximately NT\$100 million higher.

台北，台灣，2025 年 6 月 9 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 5 月自結合併營收為新台幣 15 億 1 仟萬元，較去年同期衰退 10.7%，累計營收年增 35.0%；若以美金計價，月營收較去年同期衰退 6.0%，造成此狀況主要因為台幣升值所致，而若以 4 月匯率計，營收約可增加新台幣 1 億元。

While **Pharma Sales** momentum continues, **CDMO business** experienced the slowest month of the year mainly due to manufacturing delays at our sterile injectable site in Maryland where half of its revenues were impacted and the Company expects the impact to be overcome and compensated in July and subsequent months. In addition, Bora's Taiwan network also experienced certain momentary shipment delay during the month. Strong order momentum for core oral dosage manufacturing in Taiwan remains unchanged.

即便全球銷售業務五月表現不俗，CDMO 業務卻繳出今年以來最疲弱的單月表現，主因馬里蘭州無菌注射劑廠生產延遲，影響該廠一半的月營收；公司表示正常生產將於 6 月恢復，預期該事件影響最遲將於 7 月補回營收。另外，台灣最大廠區該月亦有部分延遲出貨狀況，但主要口服生產產能接单暢旺態勢不變，預期營收時間差為短期影響。

The Taiwan CDMO network is also nearing completion of the tech transfer projects of Upsher-Smith generics products. These transferred products are expected to benefit from stronger cost structure hereafter, further lifting Bora's operational excellence.

台灣廠區亦接近完成美國 Upsher-Smith 產品轉廠生產的技轉專案，技轉商品後續銷售將貢獻較佳的毛利率，進一步推升保瑞營運動能。

Recent Investor Conference

Bora will participate in the Goldman Sachs China Healthcare Conference in HK on June 24th. For 1:1 meetings with management, please contact your GS representative.

法說會資訊

- 保瑞將於 6 月 24 日於香港參加 Goldman Sachs China Healthcare Conference，您希望與管理層面對面會議請聯繫您的 GS 業務。

About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracorpcdmo.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracorpcdmo.com>

Investor/Media enquiries

Nadiya Chen, Investor Relations

+886 2 790-1555 Ext. 9108

Email: Nadiya.Chen@bora-corp.com

新聞聯繫人：

投資人關係 陳荻雅

電話：(02) 2790-1555 #9108

Email: Nadiya.Chen@bora-corp.com